# An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes

> **NCT02962492** · NA · COMPLETED · sponsor: **University at Buffalo** · enrollment: 70 (actual)

## Conditions studied

- Evaluate Ketogenic Stress

## Interventions

- **DRUG:** Exenatide/Exenatide extended release
- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02962492
- **Lead sponsor:** University at Buffalo
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-01
- **Primary completion:** 2021-02-01
- **Final completion:** 2021-10-24
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02962492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02962492, "An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02962492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*